March 9, 2018 06:47 AM EST

Xeris hauls $55M in new funding to bring glucagon pen to market

Brittany Meiling

Chicago’s Xeris Pharmaceuticals has $55 million in new money to work as the company preps to take its lead investigational product – a glucagon rescue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Xeris hauls $55M in new funding to bring glucagon pen to market

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Xeris hauls $55M in new fund­ing to bring glucagon pen to mar­ket

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Xeris hauls $55M in new funding to bring glucagon pen to market

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?